Wedbush Cuts Perspective Therapeutics Price Target to $9, Keeps Outperform
Wedbush lowered its price target to $9 from $11 while maintaining an Outperform rating.
Wedbush lowered its price target to $9 from $11 while maintaining an Outperform rating.